Leading Ocular Oncology: Dr. Reichstein at ISOO 2026
At the Forefront of Ocular Oncology: Dr. Reichstein Represents Tennessee Retina at ISOO 2026
Tennessee Retina is proud to share that Dr. Reichstein and members of our Oncology team were selected to present multiple research studies at the International Society of Ocular Oncology (ISOO) Meeting in Rio de Janeiro.
The International Society of Ocular Oncology (ISOO) is an international society of ocular oncologists and affiliated professionals, bringing together leading experts from around the world every two years to share the latest research, innovations, and clinical advancements in ocular oncology.
This year’s meeting was highly competitive, with nearly 350 abstracts submitted and only 75 accepted for presentation. Tennessee Retina is honored that every abstract submitted by our team was selected, a significant achievement that reflects the strength and impact of our research efforts and reinforces our role at the forefront of ocular oncology care.
Advancing Research in Ocular Oncology
Dr. Reichstein served as first author and presenter on the study:
“Preliminary Clinical Outcomes of Neoadjuvant Darovasertib in Primary Uveal Melanoma: Tumor Regression, Eye Preservation, and Maintenance of Visual Function.”
Tennessee Retina has the largest international patient cohort enrolled in this study
In addition to this presentation, Dr. Reichstein also contributed as a co-author on several studies presented at ISOO:
-
Towards a Molecular Definition of Malignant Transformation in Small Uveal Melanocytic Tumors
Role: Co-Author -
Effect of Cytopathology Confirmation on the Prognostic Accuracy of GEP/PRAME in Uveal Melanoma in the Collaborative Ocular Oncology Group 2 (COOG2) Study
Role: Co-Author -
Study of Ophthalmic Radiation Therapy Toxicity (SORTT): An Interim Report
Role: Co-Author -
Prognostic Accuracy of Driver Mutations Versus 15-GEP/PRAME in Uveal Melanoma
Role: Co-Author
Additional recognition to our Oncology Services Supervisor, Anderson Brock, for serving as first author on "Combined Excision plus Plaque Brachytherapy and Immunotherapy for Conjunctival Melanoma" -with contributions from Dr. Reichstein and Jamie Cohen.
A Commitment to Leading-Edge Care
Being selected across the board highlights Tennessee Retina’s continued commitment to advancing research and staying at the forefront of ocular oncology care.
